Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Rapid access to investigational vaccines: an analysis of access provisions

An analysis of how large pharmaceutical companies are responding to the global need for accessible and affordable vaccines through access-oriented R&D. The study analyses data submitted to the 2014 Access to Medicine Index.

Date

30 September 2015

Download this publication

The world’s largest pharmaceutical companies are developing promising new vaccines to tackle some of the world’s highest-burden diseases. This pipeline includes a group of first-ever vaccines, which, if successful, will finally make it possible to immunise children against diseases such as dengue, HIV/AIDS, malaria and tuberculosis. Yet, at least one key question remains: how soon will these vaccines be accessible and affordable in the countries that shoulder the largest burdens from these global killers?

For the majority of the pipeline, it is not clear whether companies are taking measures to ensure future vaccines will be affordable and available in sufficient quantities to low- and middle-income countries. To help payers and procurers plan ahead, companies are strongly encouraged to put access strategies and access provisions in place early in the R&D process for vaccines, and to off er details of these provisions and their planned implementation.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved